Brain bioenergetic function declines in some neurodegenerative diseases, this may influence other pathologies, and administering bioenergetic intermediates could have therapeutic value.
INTRODUCTION
Declining bioenergetic function is recognized as a cause, component, or consequence of brain aging and neurodegeneration (1) . Respiratory chain enzyme activities, specifically those with mitochondrial DNA (mtDNA)-encoded components, fall with advancing age (2) . In normal brain aging, this may induce presumably compensatory changes such as increased brain mtDNA levels (3). For age-related diseases such as Alzheimer's disease (AD), this compensation is less obvious (4) . In AD, PCR-amplifiable mtDNA levels decrease as do mRNA and protein levels of peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC1α), a transcriptional coactivator that promotes mitochondrial biogenesis (5) (6) (7) (8) . Observations such as these identify mitochondria as therapeutic targets for brain aging, as well as for neurodegenerative diseases that show mitochondrial dysfunction (9) . "Mitochondrial medicine" approaches are being considered for the treatment of neurodegenerative diseases (10) . One approach is the induction of mitochondrial biogenesis, which could benefit bioenergetic capacity by upregulating aerobic infrastructures. Bioenergetic capacity, though, does not pertain just to mitochondria since ATP and reducing equivalents are also generated in the cytoplasm. For this reason we have proposed a new term, bioenergetic medicine, which applies to strategies specifically designed to increase cell energy levels regardless of whether they directly or indirectly target mitochondria (11) . 
Effect of OAA on genes and proteins related to mitochondrial biogenesis and bioenergetics
Mitochondrial biogenesis is regulated through the PGC1-family proteins (21) . These cotranscriptional activators, which promote mitochondrial biogenesis, include PGC1α, PGC1β, and PGC1 related co-activator (PRC). Brain PGC1α mRNA levels were 58% higher in the 2 g/kg/day group than they were in the control group, and for the combined OAA group (all mice treated with OAA, whether at 1 g/kg/day or 2 g/kg/day) it was 37% higher ( Figure 1A ). Although brain PGC1α protein levels did not increase to a statistically significant extent (Table   S1 , Figure S1A ), PGC1α protein within cells redistributed such that its nucleus:cytoplasm ratio increased; the nucleus:cytoplasm ratio approximately doubled in both the 1 and 2 g/kg/day groups ( Figure 1B , Figure S1A , Table S1 ).
Brain PRC showed similar changes. PRC mRNA was 47% higher in the mice receiving 2 g/kg/day than it was in the control mice ( Figure 1C ). For the PRC nucleus:cytoplasm ratio, while the ANOVA value was not significant (p=0.09), a post hoc analysis suggested the PRC nucleus:cytoplasm ratio was higher (by 70%) in the 2 g/kg/day group ( Figure 1D , Figure S1A ).
This difference was primarily driven by a relative decrease in the cytosolic PRC protein level (Table S1 , Figure S1A ).
No statistically significant changes were seen in brain PGC1β mRNA levels, PGC1β protein levels, or PGC1β protein distribution ( Figure 1E -F, Table S1 ). Despite this, mice treated with OAA showed PGC1β trends that reflected the PGC1α and PRC changes. For OAA treated mice, the mean mRNA levels were approximately 1.25 (versus 1.00 in the control group), and the mean nucleus:cytoplasm ratio in the 2 g/kg group was 2.00 (versus 1.00 in the control group).
Other evidence suggested OAA stimulated brain mitochondrial biogenesis. For the combined OAA group, mRNA levels of nuclear respiratory factor 1 (NRF1), a PGC1α-co- 6 activated transcription factor that promotes the expression of nuclear genes that encode mitochondrial proteins (21) , increased by 20% (Figure 2A ). Measurements of transcription factor A of the mitochondria (TFAM), a gene whose expression is driven by the PGC1α-NRF1 complex (21) , validated this change. Although the TFAM mRNA level ANOVA was not significant (p=0.06), post-hoc analysis suggested TFAM mRNA was higher (by 30%) in the 2 g/kg/day OAA group (Figure 2B ). OAA treatment also increased cytochrome oxidase subunit 4 isoform 1 (COX4I1) mRNA and protein levels. COX4I1 mRNA rose approximately 45% in the OAA-treated groups ( Figure 2C ). COX4I1 protein was 60% higher in the 1 g/kg/day group, and 30% higher in the 2 g/kg/day group ( Figure 2D , Figure S1B ).
Significant changes in other mitochondrial biogenesis-related gene expression were not observed in the brains we studied. Nuclear respiratory factor 2 (NRF2), NADH Dehydrogenase Ubiquinone Fe-S Protein 2 (NDUFS2), NADH dehydrogenase subunit 2 (ND2), and cytochrome oxidase subunit 2 (COX2) mRNA levels were comparable across the groups (Table S2) . TFAM protein levels were unchanged (Table S1 ). mtDNA levels were also comparable between the groups (Table 1) .
PGC1α is regulated by other proteins that are sensitive to bioenergetic states. HIF1α facilitates glycolysis flux, generally counters aerobic flux, and may negatively regulate PGC1α (22) . Brain HIF1α protein levels did not increase and no intracellular redistribution was observed (Table S1 ). Silent information regulator of transcription 1 (SIRT1) is a deacetylase that activates PGC1α (23) . SIRT1 mRNA levels did not change (Table S1) . No statistically significant differences in SIRT1 protein levels or distribution were seen, although cytoplasmic SIRT1 protein perhaps trended lower in the OAA treated mice (p=0.08 between the control and both the 2 g/kg/day and combined OAA groups) (Table S1 ).
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Adenosine monophosphate-activated protein kinase (AMPK) monitors cell AMP:ATP, low AMP:ATP ratios and increased cytosolic calcium promote AMPK phosphorylation at Thr172, and Thr172 phosphorylation positively correlates with its kinase activity (24) . PGC1α is an AMPK target, and AMPK-mediated PGC1α phosphorylation activates PGC1α (25) . We observed increased brain AMPK Thr172 phosphorylation in both the 1 g/kg/day OAA (three-fold increase) and combined OAA groups (two-fold increase) ( Figure 3A -B, Figure S1C) . Similarly, the p38 MAPK phosphorylates PGC1α and this too is an activating phosphorylation (26) . We detected evidence of brain p38 MAPK activation in the 1 g/kg/day OAA group as p38 phosphorylation, which positively correlates with its activation state, increased by 92% when normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ( Figure 3D , Figure S1C ). p38 phosphorylation was not significantly increased after normalizing levels to total MAPK, perhaps because total p38 also trended higher in the 1g/kg/day OAA group (Figure 3C, Figure   S1C , Table S1 ). Finally, phosphorylation at Ser133 of cAMP-response element binding (CREB) protein, a modification that directly correlates with its activation state (27) , occurred within the brain ( Figure 3E -F, Figure S1C ). CREB is known to stimulate PGC1α gene expression (28) .
Effect of OAA on insulin signaling pathway proteins
A tissue's bioenergetic status influences its sensitivity to insulin, or at least the activation state of its insulin signaling pathway (19) . We therefore assessed OAA's impact on that pathway in the brains of our OAA-treated and untreated mice. Part of the signal produced when insulin binds its receptor is transmitted via Akt, which is activated through phosphorylation of its Ser473 site (29) . Akt Ser473 phosphorylation increased in a dose dependent manner; with the 2 g/kg/day treatment there was more than a three-fold increase ( Figure 4A -B, Figure S1D ). Total Akt levels were unchanged (Table S1, Figure S1D ). The insulin pathway also includes mammalian target of rapamycin (mTOR), and the activity of the pathway positively correlates with the amount of mTOR phosphorylation at its Ser2448 site (30) . mTOR Ser2448 phosphorylation increased; at the 2 g/kg/day dose, the phospho-Ser2448 mTOR/total mTOR ratio rose almost three-fold ( Figure 4C-D, Figure S1D ). The amount of total mTOR protein and its nucleus:cytoplasm distribution were unchanged (Table S1, Figure S1D ). Thr389 phosphorylation of P70S6K, a protein which is likely both a downstream target of mTOR and a protein that phosphorylates mTOR (31) , also increased in OAA-treated mice (by 81% in the 1 g/kg/day group and by 70% in the combined OAA group) ( Figure 4E -F, Figure S1D ), while total P70S6K protein levels remained comparable across the groups (Table S1, Figure S1D ).
Effect of OAA on brain inflammation
To assess the effects of OAA administration on brain inflammation, we measured mRNA levels for two inflammation-related genes, tumor necrosis factor α (TNFα) and C-C motif chemokine 11 (CCL11) (32, 33) . While hippocampal TNFα levels were comparable across the groups, hippocampal CCL11 mRNA levels were 44% lower in the group receiving 2 g/kg/day than they were in the control group ( Figure 5A -B). The amount of nuclear factor κB (NFκB) protein, a transcription factor that translocates to the nucleus when inflammation is present (34) , was lower in the nucleus of the combined OAA treatment group (by 50%), and in both OAA treatment groups the nucleus-to-cytoplasm ratio was approximately 70% lower than it was in the control group ( Figure 5C -D, Figure S1E ).
Effect of OAA on neurogenesis
Neurogenesis persists in the adult mouse brain (35) , and one site that maintains neurogenesis throughout even late human adulthood is the subgranular layer of the hippocampal dentate gyrus (36, 37) . It was previously reported in mice that CCL11 retards subgranular layer neurogenesis (33) . Because CCL11 gene expression was reduced in the hippocampus of OAAtreated mice, and because Akt and mTOR activation promotes cell growth (29, 38) , we evaluated hippocampal neurogenesis. We measured hippocampal mRNA levels for two genes recognized to promote neurogenesis, brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor A (VEGF) (39, 40) . Although BDNF gene expression was unchanged, VEGF gene expression was 25% higher in the combined OAA group than it was in the control group ( Figure 6A-B) . The VEGF protein level itself was not elevated (Table S1 ), but it is important to note mRNA was measured from a hippocampus-enriched region while protein was measured from hemisphere tissue. We further measured mRNA levels for doublecortin (DCX), a gene whose protein product indicates neuron immaturity (41) . DCX can be used as a surrogate measure of new neuron formation, with higher levels suggesting increased neurogenesis (42) .
Relative to the control group, DCX mRNA was increased by 81% in the 1 g/kg/day OAA group and by 48% in the 2 g/kg/day group ( Figure 6C ).
Next, we prepared sections of the remaining hippocampus (the right hippocampus). We were able to identify a relatively intact dentate gyrus in sections from ten control, seven 1 g/kg/day, and nine 2 g/kg/day OAA-treated mice. These sections were stained with a primary antibody to DCX ( Figure 6D ). Relative to the control group, DCX pixel density in the dentate gyrus was 73% higher in the 2 g/kg/day OAA group ( Figure 6E ). The number of DCX-positive neurons was increased by 44% in the 1 g/kg/day group and by 120% in the 2 g/kg/day group ( Figure 6F ). Relative to the control group, DCX-positive neurites were 28% longer in the 1 g/kg/day OAA group, and 48% longer in the 2 g/kg/day OAA group ( Figure 6G ).
Effect of OAA on in vivo levels of key neurochemicals
Proton magnetic resonance spectroscopy ( 1 H-MRS) was performed on mice before receiving any treatment, and on the same mice after they received 2 g/kg/day OAA IP for one week (the 1 g/kg/day dose was not studied). OAA induced changes in several brain biochemical intermediates. After one week of OAA, brain lactate, GABA, and glutathione (GSH) levels were respectively 21%, 15%, and 27% higher than they were on the pre-treatment scans ( Figure 7A -C). Non-significant trends towards increased glutamate (6% mean increase, p=0.14) and glutamine (13% mean increase, p=0.07) were observed, while aspartate was essentially unchanged (1% mean decrease after treatment, p=0.95) ( Figure 7D -F).
DISCUSSION
We administered OAA to mice and tested its ability to alter brain bioenergetic infrastructures, insulin signaling, inflammation, and neurogenesis. OAA increased levels of a mitochondrial protein and positively altered proteins that up-regulate mitochondrial mass, activated the insulin signaling pathway, reduced two inflammation-related parameters, and increased new neuron formation in the hippocampus. While some bioenergetic intermediates such as lactate or pyruvate can enhance respiration, these metabolites lie at the end of the glycolysis pathway and increasing levels can reduce glycolysis flux (43) . OAA is not a glycolysis intermediate, and is less likely to inhibit glycolysis. Oxidation of OAA to malate converts NADH to NAD+, which may enhance glycolysis flux, increase mitochondrial mass, and mimic caloric restriction (44, 45) . Malate, OAA's redox partner, crosses mitochondrial membranes and can have anaplerotic or cataplerotic effects on the Krebs cycle (46) . OAA induced changes that suggest an overall pro-mitochondrial effect. Levels of COX4I1 protein, a nuclear-encoded cytochrome oxidase subunit, increased. While this by itself does not prove increased mitochondrial biogenesis, elevated mRNA copy numbers for two PGC1 family members (PGC1α and PRC) were observed. PGC1α and PRC protein also shifted to the nucleus. These changes would arguably support mitochondrial biogenesis. Increased TFAM and NRF1 mRNA levels are consistent with this view. CREB, a transcription factor that promotes PGC1α expression (28) , was more extensively phosphorylated at a residue that reflects its activity. AMPK and p38 MAPK proteins were more extensively phosphorylated at residues that correlate with their activation state, and AMPK and p38 MAPK in turn activate PGC1α (25, 26) . For these reasons, we conclude that mitochondrial biogenesis was at least to some extent activated. This effect could prove useful for treating brain diseases in which mitochondrial mass parameters and PGC1α levels decline, as they do in AD (7, 8) .
It is nevertheless important to note the most straightforward pro-mitochondrial biogenesis changes we report occurred at the mRNA level. In some cases, increases in specific mRNA molecules were accompanied only by inter-compartmental shifts of the corresponding protein; in other cases no corresponding changes in the corresponding protein (either at the total level or in the distribution pattern) were observed. These outcomes, we believe, at least partly reflect the complexities of documenting mitochondrial biogenesis. For instance, we previously found mitochondria in different tissues, when stimulated to increase their mitochondrial mass, can selectively up-regulate only the components that are functionally needed at that time (47) .
Further to this point, while the brains of elderly mice certainly do manifest evidence of bioenergetic stress (2), the brains of the young mice used in this study presumably lacked bioenergetic stress and may have limited the up-regulation of mitochondrial components (including specific proteins and mtDNA). Also, the function of proteins that mediate mitochondrial biogenesis may be influenced more by post-translational modifications than by absolute levels, and our study was not designed to comprehensively characterize the posttranslational modifications of all the proteins we analyzed. Finally, from an anatomic perspective, our gene expression studies utilized a hippocampus-enriched region, while our protein and mtDNA studies excluded the hippocampus. Overall, therefore, we believe the pattern of changes observed support the conclusion that mitochondrial biogenesis signaling was at least activated, and for some endpoints (for example, COX protein) successfully executed.
Insulin signaling is influenced by bioenergetics (19) . In at least some tissues impaired mitochondrial function causes insulin resistance (48) . In AD subjects brain insulin pathway signaling is markedly reduced, and for this reason some investigators consider AD a form of diabetes (49) . OAA enhanced the brain's insulin signaling pathway as evidenced by an increase in Akt Ser473 phosphorylation, mTOR Ser2448 phosphorylation, and P70S6K Thr389 phosphorylation. We expect this reflects intracellular effects rather than a direct impact on insulin receptors. This property could prove useful for treating brain diseases in which the insulin signaling pathway is de-activated.
Neuroinflammation occurs in AD and other neurodegenerative diseases (50) . In various tissues, inflammation has been linked to damaged mitochondria or declines in mitochondrial function (51) (52) (53) . We hypothesized, therefore, that promoting mitochondrial function would reduce inflammatory markers. We did not detect a statistically significant change in TNFα mRNA, perhaps because in young mice microglial TNFα expression is already very low. mRNA levels of CCL11, though, a chemokine produced by macrophages and neurons (54) , were lower in OAA treated mice.
Consistent with this, nuclear protein lysates from OAA-treated mice contained less NFκB protein, as well as lower NFκB nuclear:cytoplasm ratios. NFκB, a transcription factor, is restrained within the cytoplasm until activated by inflammatory cytokines and other cell-stress events (55) . When activated, NFκB's restraint is removed and it moves to the nucleus. Since NFκB promotes the CCL11 gene (56) , reduced NFκB may account for lower CCL11 expression.
OAA, therefore, could prove useful for treating brain diseases in which neuroinflammation occurs.
In humans and other mammals, stem cells in the subgranular layer of the hippocampal dentate gyrus generate new neurons throughout adulthood (35) (36) (37) 57) . The rate of neurogenesis declines to some extent with advancing age (35, 36) . It is speculated this rate may further fall in AD, but few studies have tried to address this question (58, 59) . We found that protein and mRNA levels of DCX increased in the hippocampi of OAA treated mice, the number of intensely DCX-positive neurons rose, and the length of DCX-positive neurites increased. We did not ascertain the mechanistic basis for these pro-neurogenesis changes, but it is worth noting CCL11 levels inversely correlate with hippocampal neurogenesis (33) and OAA treatment lowered hippocampal CCL11 gene expression. In addition, OAA treatment enhanced the brain insulin signaling pathway, which is a pro-growth pathway. Finally, VEGF mRNA levels were higher in hippocampi from OAA-treated mice. VEGF is mostly recognized for its role in angiogenesis, but it also promotes neurogenesis (40, 60) . VEGF expression is regulated by HIF1α (61), a transcription factor which did not appear altered by OAA, but also by PGC1α (62), which OAA seemed to positively effect.
While relationships between hippocampal neurogenesis and memory are not entirely understood (63) , in aged rodents promoting hippocampal neurogenesis associates with improved performance on memory tasks (35) . Therefore, this effect may prove useful for treating AD, a disorder clinically characterized by hippocampal atrophy and memory decline. Our gene expression studies utilized a hippocampus-enriched region, while our protein and mtDNA studies excluded the hippocampus. This could account for occasional observed discordance between our gene expression and protein data. We cannot exclude the possibility that pyruvate, the decarboxylation product of OAA, mediated some effects. However, because pyruvate levels increased only to a limited extent after OAA was placed into solution, we expect OAA was primarily responsible. We cannot exclude the possibility that observed effects were an indirect consequence of a biochemical change arising outside the brain (68), but due to the extent of the observed brain changes we think indirect effects could account for only a limited part of the observed changes.
This study was intended to pre-clinically evaluate a new potential treatment for AD and other neurodegenerative diseases. AD and other neurodegenerative diseases, though, are chronic disorders and the treatment duration in our study lasted only two weeks. Should clinical studies show a beneficial effect, chronic treatment would likely be required. If so, the route through which OAA is delivered could impact this intervention's feasibility. Our study also has implications for the recently defined bioenergetic medicine field (11), which emphasizes bioenergetic intermediates can be used to manipulate bioenergetic fluxes and this, in turn, can have protean molecular effects. In this respect, it should be noted that altering the concentrations of other bioenergetic intermediates, for example increasing levels of beta-hydroxybutyrate through ketogenic diets or by simply administering medium chain triglycerides, has been proposed and studied for the treatment of AD (69-71).
We do not know what blood and brain levels resulted from the IP injections we administered. Addressing this will facilitate the planning of rational clinical trials that test the efficacy of OAA in human subjects with AD and other neurodegenerative diseases. Overall, though, as systemically administered OAA appears to activate brain bioenergetics-related proteins, enhance the insulin signaling pathway, reduce neuroinflammation, and stimulate neurogenesis further therapeutic development is indicated.
MATERIALS AND METHODS

Mice and OAA Treatments
The University of Kansas Medical Center's Institutional Animal Care and Use Committee approved these experiments. Male, five-month old C57Bl/6 mice from the Jackson Laboratory were accommodated to our vivarium for one week, housed up to five per cage in clear plastic cages on a 12:12 hour light:dark schedule, and given ad libitum access to standard chow and water.
We tested the stability of our OAA solutions by using a colorimetric-based kit (Eton Bioscience) that measures the pyruvate concentration of pyruvate, the decarboxylation product of OAA, in solution. Immediately prior to use, OAA solutions were prepared by dissolving OAA in phosphate-buffered saline (PBS) and pH-adjusted with NaOH. For 1g/kg/day OAA injections, 600 mg of OAA was suspended in 10 ml of PBS (0.45 M) and pH-adjusted to 7.0. For 2g/kg/day OAA injections, 1.2 g of OAA was suspended in 10 ml of PBS (0.9 M) and pH-adjusted to 7.0.
A target pH of 7.0 was used because over time the pH of the OAA solutions drifted towards more alkaline levels. The vehicle-treated group received PBS. For each group the total volume received via IP injection was 500 µl. 1 g/kg and 2 g/kg doses were selected based on a previous study that reported 1 g/kg IP OAA injections affect mouse seizure threshold (16), and our own preliminary studies that showed C57Bl/6 mice routinely survived 2 g/kg but not 3 g/kg OAA IP injections. For all studies except the 1 H-MRS studies the treatment period lasted two weeks; for 1 H-MRS studies the treatment period lasted 1 week.
Immunochemistry, Gene Expression, and mtDNA Levels
Mice analyzed for immunochemistry, gene expression, and mtDNA levels were treated for two Protein lysates were prepared from the left hemisphere cortices using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific), according to the manufacturer's instructions. Protein concentrations were measured using a BCA protein assay kit (Thermo Scientific). Protein aliquots were electrophoresed within 4-20% Criterion TGX Tris-glycine polyacrylamide gels (Bio-Rad) and transferred to nitrocellulose membranes (Invitrogen). Blots were stained with primary antibodies to the proteins listed in Table S3 . To ensure equivalent protein loading, blots with cytosolic lysates were stained with an antibody to GAPDH, while blots with nuclear lysates were stained using an antibody to histone deacetylase 1 (HDAC1) or histone 3 (H3). Primary antibody binding was detected using horseradish peroxidase-conjugated secondary antibodies (1:2000 dilution; Cell Signaling Technology) and SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). Densitometry was performed using a ChemiDoc XRS with Quantity One software (BioRad).
Total RNA was prepared from the left hippocampus-containing region using TRI Reagent (Life Technologies). Reverse transcription was performed on total RNA (1 μg) using an iScript RT qPCR master mix (BioRad). Amplifications were performed using an Applied Biosystems 7300 PCR System. Quantitative real-time, reverse-transcription PCR (qPCR) used iTaq universal probes supermix (BioRad) and TaqMan Gene Expression Assays (Applied Biosystems) to quantify mRNA levels for the following genes: PGC1α, PGC1β, PRC, NRF1, NRF2, TFAM, SIRT1, CREB, NDUFS2, COX4I1, COX2, ND1, TNFα, CCL11, BDNF, VEGF, and DCX. Actin expression served as a reference.
To quantify brain mtDNA, approximately 30 mg of hemisphere tissue was placed in 600 µl of lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1% SDS) and Dounce homogenized using 10 strokes. Homogenized tissue was transferred to a microcentrifuge tube, 60 µl of proteinase K (Qiagen) was added, and the tubes were vortexed and incubated at 55° for 2 hours.
Samples were vortexed every 30 minutes during the 2 hour incubation period. Samples were next centrifuged at 8,000 g for 15 minutes, and the supernatants were transferred to new tubes. 600 µl of phenol:chloroform:isoamyl alcohol (Sigma) was added and the tubes were vortexed and then centrifuged at 8,000 g for 15 minutes. Supernatants were transferred to new tubes, 500 µl of chloroform (Sigma) added, and samples were vortexed and centrifuged at 8,000 g for 15 minutes. The supernatants were transferred to new tubes, 40 µl of 3 M sodium acetate and 440 µl of 100% isopropanol were added, and samples were incubated at -20°C overnight. Samples were next centrifuged at 8,000 g for 15 minutes, the supernatants were discarded, and the pellets were washed with 750 µl of 70% ethanol and centrifuged at 8,000 g for 8 minutes. Supernatants were discarded, and the pellets were washed with 500 µl of 70% ethanol and centrifuged at 8,000 g for 8 minutes. The pellets were gently air dried and re-suspended in 100 µl of nuclease-free water.
To obtain relative mtDNA:nuclear DNA ratios, TaqMan Gene Expression Assays for two mtDNA-encoded genes, ND2 and 16s ribosomal RNA (rRNA), and the nuclear 18s rRNA gene were used. Ratios were determined using the comparative ∆∆CT method, in which ND2:18s rRNA and 16s rRNA:18s rRNA ratios were calculated.
Immunohistochemistry
Tissue was fixed in 4% paraformaldehyde overnight and cryopreserved in sequential incubations overnight in 10% sucrose, 20% sucrose, and finally 30% sucrose at 4°. Tissue was flash-frozen in Optimum Cutting Temperature (OCT) compound. 10 µm sections were obtained using a cryostat set to -25°, and tissue sections were transferred to Superfrost Plus microscope slides (Fisher Scientific). Antigen retrieval was completed using sodium citrate buffer (10 mM plus 0.05% Tween-20, pH 6.0) for 10 minutes at 100°C. Slides were equilibrated to room temperature for 20 minutes and washed in PBS 3 times. Slides were then stained with the DCX primary antibody (Abcam ab18723, 1:500), an Alexa Flour 488 secondary antibody (Abcam ab150073, 1:500), and ProLong Gold Antifade reagent with DAPI (Invitrogen, Life Technologies).
Images were captured using a Leica TCS SPE confocal microscope platform with an LAS AF interface at 10X. Each section that was subsequently found to contain recognizable dentate gyrus was analyzed. All images were captured using the same parameters. Image analysis was completed using LAS AF lite software.
In Vivo 1 H-MRS
1 H-MRS scans were obtained at 9.4 tesla (Varian Inova) on 8 isoflurane-anesthetized mice before and after a 1 week 2 g/kg/day IP OAA course. Post-treatment brain scans were acquired 3.5 hours after the final OAA injection. Scanning methods were adapted from Harris et al (72) .
Briefly, mice were placed on a heating pad in the scanning cradle and core temperature was maintained at 37 ºC. Isoflurane was adjusted (1-2%) to maintain a respiration rate of 110-160/min. Gradient echo multi-slice images were used to position the mouse's head in the magnet isocenter (TR = 65 ms, TE = 2.8 ms), followed by rapid acquisition with relaxation enhancement and TR = 4000 ms (73) . Spectra were analyzed with LCModel software, using the unsuppressed water signal for each scan to calculate absolute metabolite concentrations as previously described (74) .
Statistics
Data were summarized by means and standard errors. To compare means between three groups we used one-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) post-hoc testing. For non-MRS analyses, to compare means between two groups we used two-way, unpaired Student's t-tests, with p-values of <0.05 considered significant. For MRS analyses, data were compared using two-way, paired t-tests. Statistical tests were performed using SPSS 18.0 (SPSS Inc). p-values less than 0.05 were considered statistically significant.
SUPPLEMENTARY MATERIAL
Supplementary Material includes 1 figure and 3 tables. #ANOVA comparison was not significant, but the post-hoc LSD test between the specified treatment group and the control group was significant at p<0.05. was more phosphorylated at Ser133 in the 1 g/kg/day, 2 g/kg/day, and combined OAA groups.
(F) When normalized to GAPDH, CREB was more phosphorylated at Ser133 in the combined OAA group. Although the ANOVA was not significant, on post-hoc analysis CREB phosphorylation was higher in the 2 g/kg/day OAA group than in the control group. Values shown are relative group means + SEM. *p<0.05; **p<0.005; #ANOVA comparison was not significant, but the post-hoc LSD test between the specified treatment group and the control group was significant at p<0.05. 
